AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion. The licensing ...

For decades, physical security teams have been conditioned to view personnel and technology investments as unavoidable expenses. Budget justification has traditionally relied on risk avoidance through ...

For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access insights report from EVERSANA (pharmaphorum's parent company). You can see the ...

Carla Tardi is a technical editor and digital content producer with 25+ years of experience at top-tier investment banks and money-management firms. Khadija Khartit is a strategy, investment, and ...

Find the best hunting gear tested by Field & Stream’s expert hunting team. Our comprehensive reviews cover everything from rifles and bows to trail cameras, optics, and hunting apparel. Each product ...

Angelica Leicht is a seasoned personal finance writer and editor with nearly two decades of experience but just one goal: to help readers make the best decisions for their wallets. Her expertise spans ...

Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain actions on our website or click to take an action on their website.

Leeron is a New York-based writer who specializes in covering technology for small and mid-sized businesses. Her work has been featured in publications including Bankrate, Quartz, the Village Voice, ...

Robert Kelly is managing director of XTS Energy LLC, and has more than three decades of experience as a business executive. He is a professor of economics and has raised more than $4.5 billion in ...

It's bad enough to roll into Darlington, S.C., less than 10 miles off Interstate 95, and realize a tough weekend lies ahead at the 1.366-mile facility dubbed "The Track Too Tough to Tame." Part of the ...